Cystic Fibrosis: Phase 1B Trial Begins for Arginase Inhibitor

Calithera Biosciences Inc has dosed the first patients in its Phase 1b clinical trial of the arginase inhibitor CB-280 in adult patients with cystic fibrosis and chronic airway infection.